Fycompa perampanel regulatory update

Eisai said it will "temporarily" suspend commercial distribution of epilepsy drug Fycompa perampanel in Germany. The move comes after Germany's Federal Joint Committee (G-BA) issued a final benefit assessment in March that found Fycompa had no additional benefit over comparators. Eisai said G-BA's comparators for Fycompa were "inappropriate" and that it is "unable to accept" the rating (see BioCentury, March 11). ...